Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma

Journal of Obstetrics and Gynaecology Research

Volumn 32, Issue 3, 2006, Pages 330-337

  Hidaka, Takao ^a   Nakamura, Takafumi ^a   Shima, Tomoko ^a   Yuki, Hiroyuki ^a   Saito, Shigeru ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Carboplatin; Chemotherapy; Endometrial adenocarcinoma; Paclitaxel; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANGIONEUROTIC EDEMA; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG HYPERSENSITIVITY; ENDOMETRIUM CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; HYPOTENSION; KIDNEY DYSFUNCTION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; POSTOPERATIVE CARE; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTOPENIA; URTICARIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; RETROSPECTIVE STUDIES;

EID: 33744488560     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2006.00405.x     Document Type: Review

References (35)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999 49 : 1.
2. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005 55 : 10 30.
3. American Cancer Society. Cancer Facts & Figures - 1997. Atlanta : American Cancer Society, 1997.
4. Pettersson F. Annual report on the results of treatment in gynecological cancer. Vol. 22. Stockholm (Sweden) : International Federation of Gynecology and Obstetrics, 1995 pp. 65 82.
5. Potish RA, Twiggs LB, Adcock LL, Prem KA. Role of whole abdominal radiation therapy in the management of endometrial cancer; prognostic importance of factors indicating peritoneal metastases. Gynecol Oncol 1985 21 : 80 86.
6. Greer BE, Hamberger AD. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation. Gynecol Oncol 1983 16 : 365 373.
7. Loeffler JS, Rosen EM, Niloff JM, Howes AE, Knapp RC. Whole abdominal irradiation for tumors of the uterine corpus. Cancer 1988 61 : 1332 1335.
8. Martinez A, Schray M, Podratz K, Stanhope R, Malkasian G. Postoperative whole abdomino-pelvic irradiation for patients with high risk endometrial cancer. Int J Radiat Oncol Biol Phys 1989 17 : 371 377.
9. Gibbons S, Martinez A, Schray M et al. Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int J Radiat Oncol Biol Phys 1991 21 : 1019 1025.
10. Piver MS, Barlow JJ, Lurain JR, Blumenson LE. Medroxyprogesterone acetate (Depo-Provera) versus hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 1980 45 : 268 272.
11. Podratz KC, O'Brien PC, Malkasian GD Decker DG, Jefferies JA, Edmonson JH. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 1985 66 : 106 110.
12. Thigpen JT, Brady MF, Alvarez RD et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999 17 : 1736 1744.
13. Thigpen JT, Brady MF, Homesley HD et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004 22 : 3902 3908.
14. Aapro MS, van Wijk FH, Bolis G et al. European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003 14 : 441 448.
15. Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1994 12 : 1408 1414.
16. Yahata H, Hirakawa T, Fujita T et al. Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer. Int J Clin Oncol 2004 9 : 317 321.
17. Hall DJ, Martin DA, Kincaid K. Filgrastim support during combination chemotherapy using cisplatin, doxorubicin, and cyclophosphamide to treat advanced or recurrent endometrial cancer: a clinical study and literature review. Eur J Gynaecol Oncol 2003 24 : 481 489.
18. Gadducci A, Romanini A, Cosio S et al. Combination of cisplatin, epirubicin, and cyclophosphamide (PEC regimen) in advanced or recurrent endometrial cancer: a retrospective clinical study. Anticancer Res 1999 19 : 2253 2256.
19. Fung MF, Krepart GV, Lotocki RJ, Heywood M. Treatment of recurrent and metastatic adenocarcinoma of the endometrium with cisplatin, doxorubicin, cyclophosphamide, and medroxyprogesterone acetate. Obstet Gynecol 1991 78 : 1033 1038.
20. Burke TW, Stringer CA, Morris M et al. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 1991 40 : 264 267.
21. Hancock KC, Freedman RS, Edwards CL, Rutledge FN. Use of cisplatin, doxorubicin, and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium. Cancer Treat Rep 1986 70 : 789 791.
22. Scudder SA, Liu PY, Wilczynski SP et al. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol 2005 96 : 610 615.
23. Akram T, Maseelall P, Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol 2005 192 : 1365 1367.
24. Michener CM, Peterson G, Kulp B et al. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J Cancer Res Clin Oncol 2005 131 : 581 584.
25. Fleming GF, Filiaci VL, Bentley RC et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 2 4-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 2004 15 : 1173 1178.
26. Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004 22 : 2159 2166.
27. Hoskins PJ, Swenerton KD, Pike JA et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001 19 : 4048 4053.
28. Fleming GF, Fowler JM, Waggoner SE et al. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol 2001 19 : 1021 1029.
29. Lissoni A, Zanetta G, Losa G, Gabriele A, Parma G, Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 1996 7 : 861 863.
30. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996 62 : 278 281.
31. Dimopoulos MA, Papadimitriou CA, Georgoulias V et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 2000 78 : 52 57.
32. Lissoni A, Gabriele A, Gorga G et al. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol 1997 8 : 969 972.
33. Ishikawa H, Fujiwara K, Suzuki S, Tanaka Y, Kohno I. Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patients. Int J Clin Oncol 2002 7 : 330 333.
34. Oliverio G, Canuti D, Tononi A et al. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients. J Chemother 1999 11 : 301 305.
35. Cantu MG, Buda A, Parma G et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002 20 : 1232 1237.